CytomX Therapeutics $100 million follow-on offering
We advised the joint book-running managers in connection with the equity offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Editas Medicine $231 million stock offering
We advised the joint book-running managers in connection with the equity offering
Innovent Biologics HK$4.73 billion placement of shares
We advised the joint placing agents in connection with the equity offering
IDEAYA Biosciences $90 million at-the-market offering
We advised the sales agent on the SEC-registered equity offering
American Well $356.8 million secondary offering
We advised Amwell on the stock offering
Affimed $115 million offering of shares
We advised the underwriters on the public equity offering
REGENXBIO $230.3 million stock offering
We advised the underwriters on a public equity offering
Generation Bio $225.4 million stock offering
We advised the underwriters on the public equity offering
NeoGenomics $230 million stock and $345 million convertible notes offerings
We advised the joint book-running managers on the public offerings of stock and convertible notes
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs